Clonidine Hydrochloride Tablet, Extended Release
NDC Package 70069-044-01
Package Information
Clonidine Hydrochloride tablets is clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)]. This formulation utilizes a tablet, extended release delivery system. Marketed by Somerset Therapeutics, Llc, this product is identified by NDC 70069-044 and is authorized under FDA application ANDA211433.
Identification & Billing
- RxCUI: 1013930 - cloNIDine HCl 0.1 MG 12HR Extended Release Oral Tablet
- RxCUI: 1013930 - 12 HR clonidine hydrochloride 0.1 MG Extended Release Oral Tablet
- RxCUI: 1013930 - clonidine hydrochloride 0.1 MG 12 HR Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70069 - Somerset Therapeutics, Llc
- 70069-044 - Clonidine Hydrochloride
- 70069-044-01 - 60 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 70069-044 - Clonidine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70069-044-01 identifies a specific commercial package of 60 tablet, extended release in 1 bottle of Clonidine Hydrochloride, a human prescription drug labeled by Somerset Therapeutics, Llc. This tablet, extended release is formulated for oral use and contains clonidine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Somerset Therapeutics, Llc on March 04, 2025. The current certification is valid through December 31, 2026.
How is this Somerset Therapeutics, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70069004401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.